BioSpace News Archive

Rocket Pharmaceuticals, Inc. today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors.

Elite Pharmaceuticals, Inc. today announced the first shipment of generic Adderall XR to its distribution and marketing partner Prasco, LLC.

Shanghai Henlius Biotech, Inc. announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer has been accepted by the National Medical Products Administration, which is the fifth indication for HANSIZHUANG accepted by the NMPA.

Alimera Sciences, Inc. today announced the appointment of Todd Wood as President U.S. effective immediately.

89bio, Inc. today announced that it closed its previously announced upsized underwritten public offering of 17,567,567 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 2,432,432 shares.

Scinai Immunotherapeutics Ltd. is pleased to announce successful preclinical trial results of its innovative anti–IL–17 VHH antibody as a local treatment for the large and underserved population of mild to moderate plaque psoriasis.

EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the French National Authority for Health (“HAS”) released a favorable recommendation for the reimbursement of high-intensity focused ultrasound (HIFU) therapy in the treatment of prostate cancer.

Mainz Biomed N.V. announced its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer detection and gastroenterological innovation.

Tome Biosciences, Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ today announced that it has been named a Leader in the Decentralized Clinical Trials (DCT) PEAK Matrix® Assessment by the Everest Group, for the third consecutive year.